tapinarof

06/01/2023 - "Beyond good efficacy and fast onset of action in patients with psoriasis, the clinical response to tapinarof is notable for durable remission or near remission, maintained for an average of 130 days beyond treatment discontinuation in patients with psoriasis in phase 3 studies. "
12/01/2012 - "Topical WBI-1001 induces rapid and significant improvement in patients with plaque psoriasis."
12/01/2022 - "Tapinarof 1% cream has shown to be effective and to have a favorable safety profile in the treatment of psoriatic patients, representing an alternative to the current therapeutic options, increasing our armamentarium in the topical treatment of psoriasis."
12/01/2022 - "Benvitimod is an effective treatment of psoriasis as compared to a placebo. "
11/09/2020 - "Benvitimod cream, a novel synthetic small molecule, was effective in treating mild-to-moderate plaque psoriasis. "

01/01/2022 - "Tapinarof, a dual agonist of the AHR/NRF2 signalling pathway, has shown promise in phase 2 trials for atopic dermatitis. "
01/01/2018 - "Study 201851 was an open-label, 2-cohort sequential study that assessed the systemic pharmacokinetics, safety, and efficacy of tapinarof in adults with moderate to severe atopic dermatitis. "
04/01/2012 - "Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial."
01/01/2023 - "A multi-center, double-blind, randomized, placebo- and positive-controlled phase II clinical study of benvitimod for the treatment of atopic dermatitis."
07/01/2022 - "Tapinarof cream 1% is also being investigated for the treatment of atopic dermatitis. "

03/01/2021 - "More patients reported AD and pruritus symptom severity as very/moderately improved in tapinarof groups, and POEM improvements were observed in all groups. "
12/01/2022 - "Patient-reported outcomes were also analyzed, yielding a significant benefit in the benvitimod group for peak pruritus numerical rating scale (PP-NRS) score (MD -1.20, 95% CI -1.98, -0.42), ≥4-point decrease in PP-NRS score (RR 1.58, 95% CI, 1.24-2.03) and dermatology life quality index score (MD -2.54, 95% CI -4.00, -1.07). "
12/09/2021 - "Adverse events with tapinarof cream included folliculitis, nasopharyngitis, contact dermatitis, headache, upper respiratory tract infection, and pruritus. "

12/09/2021 - "Tapinarof 1% cream once daily was superior to vehicle control in reducing the severity of plaque psoriasis over a period of 12 weeks but was associated with local adverse events and headache. "
01/01/2022 - "Adverse events associated with tapinarof application were folliculitis, contact dermatitis, and headache. "
12/09/2021 - "Adverse events with tapinarof cream included folliculitis, nasopharyngitis, contact dermatitis, headache, upper respiratory tract infection, and pruritus. "

01/01/2021 - "Tapinarof-associated folliculitis is generally mild, self-limiting, and rarely interferes with therapy."
01/01/2021 - "Tapinarof-induced folliculitis: The paradigm of activation of the aryl hydrocarbon signaling pathway."
01/01/2022 - "Adverse events associated with tapinarof application were folliculitis, contact dermatitis, and headache. "
12/09/2021 - "Adverse events with tapinarof cream included folliculitis, nasopharyngitis, contact dermatitis, headache, upper respiratory tract infection, and pruritus. "